Zevra’s Rene Braeckman, PhD, will present the top-line results from the phase 2 trial evaluating the safety and tolerability of KP1077 for idiopathic hypersomnia at Sleep Europe 2024.
Interim data from Zevra Therapeutics' phase 2 clinical trial of KP1077 in patients with idiopathic hypersomnia indicates the drug is well-tolerated at all tested doses and dosing schedules.
The drug developer expects to initiate a phase 2 clinical trial in patients with idiopathic hypersomnia before year-end 2022 and a second trial in patients with narcolepsy in 2023.
Read More